Arthur J. Hiller


Boston, Massachusetts


Innovative, experienced leadership in a broad range of disease and therapeutic categories, and convergent life science spaces


Pharmaceuticals, biotech, medical devices, healthcare information technology, and managed care

About Me

I’ve accumulated more than 30 years of experience across a wide range of functional areas and sectors of the life sciences and healthcare technology industry…senior leadership roles in setting strategy, building and expanding Commercial Operations, launching and marketing products, new product development, sales management, dealmaking and corporate development.  Over the last 10 years, I have been Chief Business Officer of an emerging digital health technology company, and CEO of SciFluor Life Sciences and Heartscape Technologies, two early stage companies in the areas of drug discovery and cardiovascular medical devices.

At SciFluor, we focused on applying a proprietary fluorination chemistry technology platform from Harvard University to discover novel new drugs and imaging agents, and at Heartscape we successfully launched a novel 80-lead electrocardiogram (ECG) technology to identify heart attacks not visible to the 12-lead ECG.  In three years, along with the Heartscape team, I raised more than $22 million in funding for the company, and built a Management and field sales team that successfully placed the PRIME ECG® technology in more than 30 prestigious medical institutions nationwide.

My current engagements include include roles as part-time CEO for Antyllus Therapeutics, a cardiovascular company discovering therapeutics to treat abdominal aortic aneurysms, and consultant and business advisor for Amasa Therapeutics and Smith Therapeutics, companies developing stem-cell based treatments for patients with glioblastoma, and cell-based therapeutics for neurodegenerative disease, respectively. Through my consulting company, Hiller Life Sciences Strategies, LLC, I provide commercial strategy consulting for a wide variety of companies, including recent engagements with a venture-backed company developing an obesity/pre-diabetes product, an early-stage microbiome company, a melanoma-focused oncology company, major multinational pharma companies launching new products in women's health and rare diseases, and an early stage diagnostic company developing a non- instrument based flow cytometry product.

Before Heartscape, I was Senior Vice President at Millennium Pharmaceuticals, responsible for the cardiovascular business unit, including sales and marketing of INTEGRILIN®, new product marketing for the Millennium pipeline, and customer segment and channel management.  I joined Millennium in 2001 as General Manager, Inflammation, and, following the Millennium acquisition of Cor Therapeutics in 2002, was subsequently named General Manager, Cardiovascular, and Senior Vice President, Global Strategic Marketing in 2003.  From a base less than $200 million prior to the Millennium acquisition, sales of INTEGRILIN ultimately hit nearly $400 million before Millennium divested the business to Schering-Plough in 2005.

Prior to joining Millennium, I worked for Merck & Co. as Vice President, Worldwide Human Health Marketing, Hospital Products, where I was involved in the global launch of AGGRASTAT® (tirofiban HCI), global marketing leadership of PRIMAXIN® (Imipenem) and pre-launch development of INVANZ® (ertapenem sodium) and CANCIDAS® (caspofungin acetate).  I also held responsibility for Merck managed care initiatives outside the United States.  Prior to my role in Merck marketing, I served as Senior Vice President, Business Development for Merck-Medco Managed Care, and focused my efforts on the conceptualization and execution of numerous alliances with pharmaceutical manufacturers to support and expand Merck-Medco disease management programs.

My industry career began at Lederle Laboratories, and I later joined Ayerst Laboratories. During my tenure at these companies, I held positions in sales, sales management, training, product management, licensing, distribution, and manufacturing. Following my Ayerst experience, I spent five years at MEDED, a clinical marketing firm where, joined by two other colleagues from Ayerst, the company realized expansive revenue and client growth with major pharmaceutical company clients and blockbuster product launches. I have a Bachelor’s Degree in Journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University.  I currently serve as a Lecturer at MIT, where I am on the faculty of the Healthcare Ventures class, and in Advisory Board, fundraising, consulting and business development capacities for a wide range of start-up and early stage companies in the Boston area.